Multidisciplinary care in Amyotrophic Lateral Sclerosis: a systematic review and meta-analysis

被引:0
作者
Filipe Emanuel Oliveira de Almeida
Anne Kelly do Carmo Santana
Fernanda Oliveira de Carvalho
机构
[1] Sergipe University Hospital of Universidade Federal de Sergipe-UFS,
[2] Health Sciences Graduate Center of Universidade Federal de Sergipe-UFS,undefined
来源
Neurological Sciences | 2021年 / 42卷
关键词
Amyotrophic lateral sclerosis; Multidisciplinary care; Survival; Quality of life; Systematic review; Meta-analysis;
D O I
暂无
中图分类号
学科分类号
摘要
Multidisciplinary care (MDC) has been the most recommended approach for symptom management in amyotrophic lateral sclerosis (ALS) but there is conflicting evidence about its effectiveness on survival and quality of life (QoL) of ALS patients. We conducted a systematic review to determine the effects of multidisciplinary care compared to general neurological care in survival and quality of life of ALS patients. A comprehensive literature search using Scopus, MEDLINE-PubMed, Cochrane, Web of Science, PEDro, and Science Direct was undertaken. Studies related to multidisciplinary care or general neurological care in ALS patients that assessed survival and quality of life and were published in the period up to and including January 2020 were included. A total of 1192 studies were initially identified, but only 6 were included. All studies that investigated survival showed and advantage of MDC over NC, and this benefit was even greater for bulbar onset patients. A meta-analysis was performed and showed a mean difference of 141.67 (CI 95%, 61.48 to 221.86), indicating that patients who received MDC had longer survival than those who underwent NC (p = 0.0005). Concerning QoL, only one study found better mental health scores related to QoL for patients under MDC. Multidisciplinary care is more effective than general neurology care at improving survival of patients with ALS, but only improves mental health outcomes related to quality of life of these patients.
引用
收藏
页码:911 / 923
页数:12
相关论文
共 240 条
[1]  
Wobst HJ(2020)The clinical trial landscape in amyotrophic lateral sclerosis—past, present, and future Med Res Rev 40 1352-1384
[2]  
Mack KL(2019)Prognostic factors in ALS: a comparison between Germany and China J Neurol 266 1516-1525
[3]  
Brown DG(2019)Epidemiology of ALS in Korea using nationwide big data J Neurol Neurosurg Psychiatry 90 395-403
[4]  
Brandon NJ(2015)Patient-Perceived Outcomes and Quality of Life in ALS Neurotherapeutics 12 394-402
[5]  
Shorter J(2009)Trends and determinants of end-of-life practices in ALS in the Netherlands Neurology 73 954-961
[6]  
Dorst J(2012)EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force Eur J Neurol 19 360-375
[7]  
Chen L(2017)Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach J Multidiscip Healthc 10 205-215
[8]  
Rosenbohm A(2017)The yin and yang of gastrostomy in the management of ALS Neurology 89 1435-1436
[9]  
Dreyhaupt J(2018)Riluzole, disease stage and survival in ALS Lancet Neurol 17 385-386
[10]  
Hübers A(2019)Non-invasive ventilation in amyotrophic lateral sclerosis Ther Adv Neurol Disord 12 1756286419857040-950